![]() ![]() The company has discovered genetic risk factors for various diseases including cardiovascular disease and cancer.Īmgen is headquartered in Thousand Oaks, California.Ĭlick here to read more recent news from deCODE.Ĭlick here to learn about our custom made photo book Iceland 2012 with the best pictures of the year. deCODE assessed Amgen's entire clinical pipeline within a month of the acquisition, delivering. “We believe Amgen’s focus and ability to incorporate our genetic research into their research and development efforts will translate our discoveries into meaningful therapies for patients,” he added.ĭeCODE Genetics was founded in Reykjavík in 1996 and is considered a global leader in analyzing and understanding the link between the genome and disease susceptibility. More broadly, Amgen's longtime chief scientific officer Sean Harper said in 2018 that 'with the acquisition of deCODE we gained an industrial capability to do population genetics' that could provide human genetic validation for any target or compound. “One of the ways to truly realize the full value of human genetics, is to make our research synergistic with drug development efforts where target discovery, validation and prioritization efforts can be accelerated,” said Kári. A new study from deCODE Genetics, a subsidiary of Amgen, is providing the world with hard data that will help to answer these questions. “This capability will enhance our efforts to identify and validate human disease targets,” he added.įounder and CEO of deCODE Genetics Kári Stefánsson said the deal would enable the company’s research to translate into therapies for patients. When the human genome was first fully sequenced, it was hailed as an overwhelming success. Bradway said in a press release that deCODE Genetics had built a world-class capability in the study of the genetics human disease. Celebrating its 25th anniversary, deCODE genetics, an Amgen subsidiary, is studying the impact of human diversity on disease, improving drug discovery and development. ![]() Photo by Páll Stefánsson.ĬEO of Amgen Robert A. The sale is expected to close before the end of the year.įrom the lab at deCode. The all-cash transaction was unanimously approved by the Amgen board of directors. Knowledge that can improve identification and risk stratification of a heart disorder that can cause sudden cardiac death. Icelandic genetic research company deCODE Genetics was sold to pharmaceutical manufacturing company Amgen today for ISK 52 billion (USD 415 million, EUR 317 million). Biotech pioneer Amgen Inc., in a bid for a big edge in using people's genetic information to find better ways to attack diseases, is buying human genetics research and analytics leader deCODE. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |